François Wilhelm

Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II Dyslipidemia

Jan Albert Kuivenhoven, Greetje J. de Grooth, Hitoshi Kawamura et al. · The American Journal of Cardiology · 2005 · 171 citations

Lipid Disorder, Type Ii Dyslipidemia, Oxysterol +8

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Guillermo Garcia‐Manero, Pierre Fenaux, Aref Al‐Kali et al. · The Lancet Oncology · 2016 · 168 citations

Family Medicine, Bone Marrow Failure, Hematology +7

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Bert H. O’Neil, Aaron J. Scott, W.W. Ma et al. · Annals of Oncology · 2015 · 140 citations · Full text

Oncology, Pancreatic Cancer, Gastrointestinal Oncology +9

Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma

Bishoy M. Faltas, David M. Goldenberg, Allyson J. Ocean et al. · Clinical Genitourinary Cancer · 2015 · 102 citations · Full text

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam et al. · Clinical Cancer Research · 2014 · 73 citations · Full text